Display options
Share it on

Commun Integr Biol. 2013 Jul 01;6(4):e24746. doi: 10.4161/cib.24746. Epub 2013 May 10.

Staurosporine: A new tool for studying phosphatidylserine trafficking.

Communicative & integrative biology

Kwang-Jin Cho, Jin-Hee Park, John F Hancock

Affiliations

  1. Department of Integrative Biology and Pharmacology; The University of Texas Medical School at Houston; Houston, TX USA.

PMID: 23986809 PMCID: PMC3737755 DOI: 10.4161/cib.24746

Abstract

The Ras GTPases comprising three main isoforms H-, N- and K-Ras operate at the plasma membrane as molecular switches in essential signaling pathways. Active concentration of the minor phospholipid phosphatidylserine in the inner leaflet of the plasma membrane contributes to the electrostatic potential that is required for K-Ras anchoring to the plasma membrane. We recently observed that staurosporine and related analogs: 7-oxostaurosporine, UCN-01 and UCN-02, long known as relatively non-specific protein kinase inhibitors, block endosomal sorting and recycling of phosphatidylserine, resulting in redistribution of phosphatidylserine to endosomes and endomembranes with concomitant mislocalization of K-Ras. Staurosporines are therefore a new tool to study phosphatidylserine trafficking. We discuss whether the mechanism of action of UCN-01, an FDA-approved staurosporine analog used as an anti-cancer therapeutic, is related to effects on phosphatidylserine subcellular distribution. Given the high prevalence of expression of constitutively active K-Ras in human cancers, we ask whether inhibitors of phosphatidylserine trafficking may have important therapeutic applications.

Keywords: Ras GTPase; UCN-01; lipid recycling; phosphatidylserine; staurosporine

References

  1. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15500-5 - PubMed
  2. Leuk Lymphoma. 2011 Dec;52(12):2284-92 - PubMed
  3. Ann Oncol. 2006 Feb;17(2):334-40 - PubMed
  4. J Biol Chem. 2012 Dec 21;287(52):43573-84 - PubMed
  5. Cell. 1989 Jun 30;57(7):1167-77 - PubMed
  6. Cell. 1990 Oct 5;63(1):133-9 - PubMed
  7. Mol Cell Biol. 1992 Jun;12(6):2606-15 - PubMed
  8. J Clin Oncol. 2001 Apr 15;19(8):2319-33 - PubMed
  9. Nat Cell Biol. 2007 Aug;9(8):905-14 - PubMed
  10. Future Med Chem. 2011 Oct;3(14):1787-808 - PubMed
  11. Invest New Drugs. 2012 Apr;30(2):741-8 - PubMed
  12. Clin Cancer Res. 2007 May 1;13(9):2667-74 - PubMed
  13. Mol Biol Cell. 2012 Jun;23(11):2198-212 - PubMed
  14. Nat Rev Mol Cell Biol. 2003 May;4(5):373-84 - PubMed
  15. J Cell Biol. 2003 Jan 20;160(2):165-70 - PubMed
  16. Annu Rev Biophys. 2010;39:407-27 - PubMed
  17. Cancer Res. 2012 May 15;72(10):2457-67 - PubMed
  18. J Biol Chem. 1997 May 30;272(22):14459-64 - PubMed
  19. Methods. 2005 Oct;37(2):165-72 - PubMed
  20. Curr Biol. 2012 Jun 5;22(11):945-55 - PubMed
  21. Nature. 1984 Aug 16-22;310(5978):583-6 - PubMed

Publication Types

Grant support